Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Alexander Y Andreev-Drakhlin"'
Autor:
Jessica Lee, Vivek Subbiah, Shuang Liu, Jason Roszik, David Hong, Funda Meric-Bernstam, John Heymach, Ramona Dadu, Kenneth Hess, Le Huang, Aparna Hegde, Alexander Y Andreev-Drakhlin, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman, Elizabeth G Grubbs, Siraj M Ali, Yasir Y Elamin, George R Simon, George R Blumenschein, Jr, Vassiliki A Papadimitrakopoulou
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Purpose The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET-depe
Externí odkaz:
https://doaj.org/article/c90d0d405f934390885cdc8e42bce7c6
Autor:
Aakash Desai, Vivek Subbiah, Jason Roszik, Jacob J. Adashek, Gilbert J. Cote, Alexander Y. Andreev-Drakhlin
Publikováno v:
Mol Cancer Ther
Activating receptor-tyrosine kinase rearranged during transfection (RET) mutations and fusions are potent drivers of oncogenesis. The recent FDA approvals of highly potent and selective RET inhibitors, selpercatinib and pralsetinib, has altered the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c68fe873b780b60b652d8673ed27ded
https://doi.org/10.1158/1535-7163.mct-21-0329
https://doi.org/10.1158/1535-7163.mct-21-0329
Autor:
Amishi Yogesh Shah, Pavlos Msaouel, Siqing Fu, Hung Le, Timothy A. Yap, Vivek Subbiah, Sarina Anne Piha-Paul, Janku Filip, David S. Hong, Funda Meric-Bernstam, Erick Campbell, Alexander Y. Andreev-Drakhlin, Aung Naing, Matthew T. Campbell, Daniel D. Karp, Shubham Pant, Jianjun Gao, Jason Roszik, Arlene O. Siefker-Radtke, Andrew W. Hahn, Omar Alhalabi, Nizar M. Tannir
Publikováno v:
Molecular Cancer Research. 19:395-402
Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cba3942736e5fbe8d3bdb1ca4eb8d845
https://doi.org/10.1158/1541-7786.mcr-20-0751
https://doi.org/10.1158/1541-7786.mcr-20-0751
Publikováno v:
J Clin Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8533695d7023afa3c4758d42f68975e0
https://doi.org/10.1200/jco.19.03354
https://doi.org/10.1200/jco.19.03354
Autor:
Pavlos Msaouel, Goar Egoryan, Omar Alhalabi, Alexander Y. Andreev-Drakhlin, Jianjun Gao, Amishi Yogesh Shah
Publikováno v:
Current opinion in oncology. 33(3)
Purpose of review Bladder cancer is the 10th most common cancer in the world and the 6th most common cancer among men. In the past few years, several new agents have been approved for the treatment of urothelial tumors. In this paper, we review the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::005186ba6990420a29ab9345b31ef04b
https://pubmed.ncbi.nlm.nih.gov/33818541
https://pubmed.ncbi.nlm.nih.gov/33818541
Publikováno v:
JCO Precision Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a58a120ee4d96e574dd757cd8c92c5f6
http://europepmc.org/articles/PMC7608524
http://europepmc.org/articles/PMC7608524
Publikováno v:
European Urology. 79:655-656
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b753ed620f22f53d6c995755d1e90edc
https://doi.org/10.1016/j.eururo.2020.08.033
https://doi.org/10.1016/j.eururo.2020.08.033
Publikováno v:
Cancer Research. 81:1221-1221
Background: Activating receptor-tyrosine kinase rearranged during transfection (RET) mutations and fusions have been recognized as potent drivers of oncogenesis in multiple malignancies. Recently, highly potent and selective RET inhibitors, selpercat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0fd2d57b64a24e45225421ed84f814cd
https://doi.org/10.1158/1538-7445.am2021-1221
https://doi.org/10.1158/1538-7445.am2021-1221
Autor:
Michael D. Jones, Jonathan Bistline, Joshua M. Korn, Yiling Lu, Javad Golji, Michael Morrissey, Dale Porter, Robert Schlegel, Andrew A. Lane, Antoine de Weck, Manway Liu, James M. McFarland, Amanda L. Creech, Giordano Caponigro, Haoxin Li, Michael V. Rothberg, Christopher Lo, Franklin W. Huang, Juliann Shih, Ali Amin Mansour, Brian J. Haas, Judit Jané-Valbuena, Joseph Lehar, Nicolas Stransky, Rehan Akbani, Alexander Y. Andreev-Drakhlin, Gordon B. Mills, Kevin Hu, Gad Getz, Jaegil Kim, E. Robert McDonald, Mahdi Zamanighomi, Andrew D. Cherniack, Kevin Hadi, Francisca Vazquez, Frank Stegmeier, Mahmoud Ghandi, William C. Hahn, Ellen Gelfand, Michael S. Lawrence, Levi A. Garraway, Barbara A. Weir, Anupama Reddy, Todd R. Golub, Prafulla C. Gokhale, Audrey Kauffmann, Marcin Imielinski, François Aguet, Brenton R. Paolella, Allison Warren, Jacob D. Jaffe, Cory M. Johannessen, Jordi Barretina, Coyin Oh, Caitlin M. Dunning, William R. Sellers, Julian M. Hess, Dmitriy Sonkin, Hong L. Tiv, David M. Weinstock, Jesse S. Boehm, Aviad Tsherniak, Kavitha Venkatesan, Yanay Rosen, Jordan E. Taylor, Yosef E. Maruvka, Craig M. Bielski, Gregory V. Kryukov
Publikováno v:
Nature, vol 569, iss 7757
Large panels of comprehensively characterized human cancer models, including the Cancer Cell Line Encyclopedia (CCLE), have provided a rigorous framework with which to study genetic variants, candidate targets, and small-molecule and biological thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4416246e7ce1f8e7abd43f7a227b03
https://escholarship.org/uc/item/0kr533f8
https://escholarship.org/uc/item/0kr533f8
Autor:
Omar Alhalabi, Marihella James, Amishi Yogesh Shah, Matthew T. Campbell, Surena F. Matin, Lianchun Xiao, Aradhana M. Venkatesan, Alexander Y. Andreev-Drakhlin, Ana Cecilia Adriazola, Sangeeta Goswami, Lidia Lopez, Leah Shaw, Arlene O. Siefker-Radtke, Jianjun Gao
Publikováno v:
Journal of Clinical Oncology. 39:487-487
487 Background: Tumors deficient in DNA mismatch repair (dMMR) exhibit a microsatellite unstable phenotype characterized by high tumor mutational burden and an immunogenic tumor microenvironment. Despite the histology-agnostic approval of pembrolizum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cad2a45ebfa95a520aa104d64a8633db
https://doi.org/10.1200/jco.2021.39.6_suppl.487
https://doi.org/10.1200/jco.2021.39.6_suppl.487